Plain-English answer
Reimbursement evidence for China market access is the evidence needed to show why a product should be paid for under Chinese insurance and hospital payment conditions. It is not identical to regulatory evidence. Regulators ask whether the product can be marketed; payers ask whether the insurance fund can afford it, whether it improves meaningful outcomes, and whether the price is justified against Chinese alternatives.
Market context
The National Healthcare Security Administration has become one of the most important healthcare market-access institutions in China. Its annual NRDL negotiations can unlock national drug reimbursement but usually require price concessions. In 2024, China reported that expanded drug coverage through price negotiations had saved patients more than 880 billion yuan as of October 2024, showing how strongly reimbursement policy shapes affordability and commercial economics.
Hospitals are also under DRG/DIP and budget pressure. A reimbursed product may still be unattractive if it increases cost within a fixed payment case group, lacks a billing pathway, or shifts cost to a department without visible performance benefit. Reimbursement evidence must therefore speak to both the insurer and the provider.
Operating model
A reimbursement evidence file should include disease burden, eligible population, Chinese standard of care, comparator price, clinical value, budget impact, patient out-of-pocket burden, hospital workflow impact, and implementation scenario. For drugs, NRDL strategy should identify whether the product is likely to enter through regular inclusion, negotiation, competitive bidding, or a later lifecycle moment. For devices, evidence may need to address coding, consumable cost, procedure time, complications, readmissions, and whether the product is exposed to centralized procurement.
Local variation matters. Benefit design differs by insurance scheme, province, city, pooling area, hospital level, inpatient or outpatient setting, and whether a product is inside the relevant catalogue. Evidence should not assume that national inclusion automatically produces equal access everywhere.
Strategic reading
The strongest reimbursement argument connects clinical value to fund stewardship. It explains what patients are currently receiving, what outcomes are poor, what costs are avoidable, and why the product's price is proportional to the value created in China. Foreign list prices and U.S. payer arguments are rarely enough.
A company should also decide what evidence is needed before the first negotiation and what can be collected after limited launch. If the product requires patient identification, companion diagnostics, specialist administration, cold chain, or monitoring, those implementation costs belong in the reimbursement story.
Implementation detail
Reimbursement evidence should include an implementation budget. If a product requires testing, infusion capacity, monitoring visits, imaging, or physician training, the payer may see more than the drug or device price. The company should show how those costs are offset or why they are justified.
Local evidence can also be decisive after national access. Provinces and hospitals may interpret policies differently, and physicians may hesitate if the patient pathway is unclear. Evidence should therefore support both national negotiation and local adoption.